S-1: Bolt Projects Secures $20M Equity Line Amid Nasdaq Delisting Threat

Bolt Projects Holdings, Inc. has secured an equity line of credit for up to $20 million from Ascent Partners Fund LLC, providing crucial capital while facing potential Nasdaq delisting and ongoing operational losses.

Summary

• Bolt Projects Holdings, Inc. (BSLK) has entered into an Equity Line of Credit (ELOC) facility with Ascent Partners Fund LLC, allowing the company to sell up to $20.0 million of its common stock at its option.
• The company issued 85,588 commitment shares to Ascent Partners Fund LLC as consideration for its irrevocable commitment to the ELOC.
• Bolt Projects Holdings, Inc. will not receive proceeds from the resale of shares by Ascent, but may receive up to $20.0 million from direct sales to Ascent under the Purchase Agreement.
• The company reported a net loss of $10.5 million for the six months ended June 30, 2025, and an accumulated deficit of $472.3 million as of the same date.
• Cash and cash equivalents stood at $1.0 million as of June 30, 2025, with a negative net working capital of $5.5 million.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next twelve months, citing insufficient cash to fund operations.
• The company faces a Nasdaq delisting threat, having received a notice on August 12, 2025, for non-compliance with minimum Market Value of Listed Securities ($50 million) and Market Value of Publicly Held Shares ($15 million) requirements.
• A hearing to appeal the delisting determination was held on September 16, 2025, with a decision pending, and the delisting action is currently stayed.
• Revenue for the three months ended June 30, 2025, increased by 2,225% to $1.302 million, and for the six months ended June 30, 2025, increased by 1,864% to $1.473 million, primarily due to increased sales of its Vegan Silk Technology Platform products.
• Gross income improved to $0.062 million for Q2 2025 (from a gross loss of $0.029 million in Q2 2024) and to $0.061 million for H1 2025 (from a gross loss of $0.075 million in H1 2024).
• Operating expenses decreased by 49% to $4.879 million for Q2 2025 and by 31% to $10.278 million for H1 2025.
• The company has focused its business entirely on the Vegan Silk Technology Platform (b-silk and xl-silk) since early 2023, discontinuing other product candidates like Mylo.
• The Vegan Silk Technology Platform is backed by 80 granted patents and 116 pending patent applications, with over $300 million invested in R&D over 13 years.
• The company relies on a single manufacturing partner, Laurus Bio in India, for its Vegan Silk products, but is validating a second and evaluating a third supplier.
• A 1-for-20 reverse stock split was effected on April 21, 2025.
• The company completed a PIPE transaction on August 14, 2025, raising approximately $4.25 million gross proceeds from the sale of 913,979 shares of common stock at $4.65 per share.
• An agreement with Southern Point Capital (Seneca) on August 1, 2025, involved exchanging $1.7 million of outstanding payables for 730,439 shares of common stock.
• The exercise prices of certain stock options were repriced to $2.42 per share on August 3, 2025, from original prices of $6.80 and $5.90, with no incremental fair value generated.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including a going concern warning and Nasdaq delisting threat, which are critical negative indicators. While there are some positive operational trends (revenue growth, reduced losses) and new financing secured, the magnitude of the risks and the potential for massive dilution outweigh these improvements, indicating a highly precarious situation.

Positives

• Revenue from the Vegan Silk Technology Platform increased significantly by 2,225% in Q2 2025 and 1,864% in H1 2025, indicating growing market acceptance for b-silk and xl-silk products.
• Gross income improved to $0.062 million in Q2 2025 and $0.061 million in H1 2025, from gross losses in the prior year periods, driven by reduced material costs and pricing discipline.
• Operating expenses decreased substantially by 49% in Q2 2025 and 31% in H1 2025, reflecting cost control measures and a focused business strategy.
• Net loss significantly reduced by 92% in Q2 2025 to $4.583 million and by 84% in H1 2025 to $10.542 million, compared to the prior year periods.
• Secured an Equity Line of Credit (ELOC) for up to $20.0 million from Ascent Partners Fund LLC, providing a potential source of capital for working capital and general corporate purposes.
• Successfully completed an August 2025 PIPE Transaction, raising approximately $4.25 million in gross proceeds.
• Resolved $1.7 million in outstanding payables through a settlement agreement with Southern Point Capital (Seneca) by issuing common stock.
• The company possesses a strong intellectual property portfolio with 80 granted patents and 116 pending patent applications, particularly for its Vegan Silk Technology Platform.
• Laurus Bio, the primary manufacturing partner, is undergoing capacity expansion, expected to add substantial capacity by the second half of 2026, which could support future growth.

Negatives

• The company has a history of net losses and negative cash flows from operations, with an accumulated deficit of $472.3 million as of June 30, 2025.
• There is substantial doubt about the company's ability to continue as a going concern, as existing cash and cash equivalents ($1.0 million as of June 30, 2025) are insufficient to fund operations for the next twelve months.
• The company faces a significant risk of delisting from Nasdaq due to non-compliance with minimum Market Value of Listed Securities and Market Value of Publicly Held Shares requirements.
• The potential sale of up to 20,085,588 shares under the ELOC represents approximately 542% dilution to current shareholders based on 3,706,197 shares outstanding as of September 22, 2025.
• The company is highly dependent on the success of its Vegan Silk Technology Platform, with limited product and brand recognition in the beauty and personal care market.
• Reliance on a single manufacturing partner (Laurus Bio) for its core products poses supply chain risks.
• A limited number of customers, distributors, and collaboration partners account for a material portion of revenue, creating concentration risk.
• The company has identified material weaknesses in its internal control over financial reporting as of December 31, 2024, which could affect financial reporting accuracy and investor confidence.
• The company's ability to use net operating losses (NOLs) to offset future taxable income may be subject to limitations due to past ownership changes.

Risks

• History of losses and negative cash flows from operations raises substantial doubt about the ability to continue as a going concern.
• Inability to generate sufficient cash to service debt obligations may force other actions that may not be successful.
• Failure to achieve or maintain profitability in the future.
• Delisting from Nasdaq if the appeal is unsuccessful, which could adversely affect liquidity and share price.
• Significant future expenses and capital expenditures to execute the business plan, with potential inability to control expenses or raise additional capital on favorable terms.
• High dependency on the success of the Vegan Silk Technology Platform, with limited product and brand recognition.
• Future biomaterial product candidates may not achieve market success, leading to insufficient revenue generation.
• Reliance on a single manufacturing partner and facility (Laurus Bio) for production, with potential disruptions from regulatory noncompliance, natural disasters, or other factors.
• Risks associated with international operations due to an international manufacturing partner (Laurus Bio in India).
• Pricing and availability of products may be impacted by factors outside of control, including raw material costs (e.g., urea) and market demand.
• Resistance from customers to price increases could negatively impact ability to gain and retain customers.
• Inability to manage rapid growth effectively could adversely affect business, results of operations, and financial condition.
• Manufacturing volume based on incorrect estimates and forecasts, leading to excess inventory or product shortages.
• Challenges in selling Vegan Silk Technology Platform products at commercial scale and commercially viable costs.
• Certain contracts granting exclusivity rights to customers may limit ability to sell products in specific markets.
• Substantial competition from incumbent materials (silicone elastomers) and other new entrants.
• Inability to coordinate with manufacturing partners to successfully scale up or sustain production.
• Financial results could vary materially from quarter to quarter and are difficult to predict.
• Dependence on key personnel, with inability to attract and retain additional skilled personnel.
• Management team has limited experience operating a public company, potentially diverting attention from day-to-day business.
• Increased shipping and freight costs may not be fully passed through to customers, impacting financial results.
• Material weaknesses in internal control over financial reporting, which if not remediated, could affect financial reporting accuracy and investor confidence.
• Attention to sustainability matters may impact business, financial results, and operating model, including potential 'greenwashing' allegations.
• Inability to adequately protect patents and other intellectual property assets, or costly litigation to enforce them.
• Reliance on trade secrets, with risk of competitors independently developing similar knowledge.
• Failure to protect confidential information and/or experience significant disruption in IT systems, including security breaches, as a remote-first company.
• Government regulations and private party actions relating to marketing and advertising of cosmetic products may restrict sales.
• Products not manufactured in compliance with legal requirements or resulting in adverse health effects could lead to reputational harm, remedial costs, or enforcement.
• Potential product liability claims if products are found defective or unsafe.
• Changes in government regulation may require modifications to operations or product formulations.
• Actual number of shares sold under the Purchase Agreement or gross proceeds are unpredictable.
• Sale and issuance of common stock to the Selling Stockholder will cause dilution to existing stockholders, and the perception of such sales could cause the stock price to fall.
• Investors buying shares at different times will likely pay different prices and experience different levels of dilution.
• Management may invest proceeds in ways with which stockholders may not agree or that may not yield significant returns.
• Global economic and financial market conditions could impact business operations, including reduced demand in key customer end-markets.
• Market price of common stock has been and may be volatile, leading to potential loss of investment.
• Acquisitions or investments in companies may divert management's attention and result in additional dilution.
• Future litigation or similar legal proceedings could have a material adverse effect on business and results of operations.
• No intention to pay dividends for the foreseeable future, requiring stockholders to rely on stock price appreciation.
• If securities or industry analysts cease publishing research or change recommendations adversely, price and trading volume could decline.
• Requirements of being a public company may strain resources, increase costs, and distract management.
• Claims for indemnification by directors and officers may reduce available funds.
• Anti-takeover provisions in the certificate of incorporation could adversely affect stockholder rights.
• Delaware Court of Chancery as the sole and exclusive forum for certain stockholder litigation matters could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company is committed to developing its Vegan Silk Technology Platform as the foundation for a high-value, scalable business with attractive costs and margins, aiming to reinvest in its broader portfolio and expand into additional sustainable materials. It expects to use proceeds from the ELOC for working capital and general corporate purposes. The company anticipates incurring significant expenses and capital expenditures to expand research, business, and manufacturing capacity. It also expects to continue efforts to reduce cost of goods and introduce new vegan silk products to expand into mass markets and potentially household and healthcare segments. The company believes its existing cash resources are insufficient to fund operations for the next twelve months and will need additional capital, with no assurance of successful financing.

Management Comments

• Our mission is to pioneer sustainable materials and lead the way to a brighter future, benefiting both humanity and the planet we call home.
• We are committed to developing the Vegan Silk Technology Platform as our foundation for a high-value, scalable business with attractive costs and margins.
• Over time, we believe this will enable us to reinvest in our broader portfolio and expand our Vegan Silk Technology Platform to include additional sustainable materials.
• We believe our product claims are truthful, not misleading, and would not cause our products to be regulated as drugs.
• We believe that utilizing a third-party manufacturing partner enables us to focus on our core competencies and maintain a capital efficient business model.

Industry Context

The company operates in the beauty and personal care market, which is undergoing a transformation driven by regulatory changes and consumer demand for sustainable solutions, moving away from synthetic materials like silicone elastomers. This market is expected to grow at a compound annual rate of 7.7% to reach $973 billion by 2030. The global silicone market, a key target for Bolt's Vegan Silk Technology Platform, is estimated between $16.7 billion and $19.9 billion, with the silicone elastomers subsector representing $6.3 billion to $10.0 billion and poised for a 6% CAGR from 2022 to 2030. Bolt aims to capitalize on this shift by offering biodegradable, film-forming, versatile, and functional ingredients as a substitute for silicone elastomers, which face increasing environmental and regulatory scrutiny.

Comparison to Industry Standards

• Bolt's Vegan Silk Technology Platform aims to replace silicone elastomers, which are widely used in the beauty and personal care market (390,000 tons annually in personal care and consumer products).
• The company faces competition from traditional silicone elastomer producers as well as other biomaterial new entrants like Givaudan Active Beauty (Silkgel), Spiber Inc. (Brewed Protein), Seevix Material Sciences (SVX), and Evolved by Nature (Activated Silk).
• Unlike some competitors, Bolt's b-silk and xl-silk are specifically positioned as alternatives to silicone elastomers, offering biodegradability and enhanced functional benefits.
• The company's strategy of focusing on high-impact, scalable innovation in biotechnology ingredients for beauty and personal care is aligned with broader industry trends towards sustainability and 'clean beauty' standards.

Management Changes

Corporate Governance

Legal Proceedings

• The company is named as a nominal defendant in Donoghue v. Golden Arrow Sponsor, LLC, a lawsuit filed on June 29, 2025, in the United States District Court for the Southern District of New York, asserting claims under Section 16(b) of the Securities Exchange Act of 1934 against Golden Arrow Sponsor, LLC.

Related Party Transactions

• On February 14, 2025, the company entered into a Settlement Agreement with Golden Arrow Sponsor, LLC (the Sponsor) regarding a $2.9 million excise tax liability. The Sponsor is obligated to use commercially reasonable efforts to provide or organize $10 million in financing by August 13, 2025, and contribute 75% of excise tax payments under a payment plan until $6 million in financing is closed or the tax is fully paid.
• As partial consideration for the Settlement Agreement, on March 5, 2025, the company exchanged private placement warrants held by the Sponsor for a new Sponsor Warrant to purchase 250,000 shares of common stock at an exercise price of $10.00 per share.
• The August 2025 PIPE Transaction on August 14, 2025, involved selling stockholders, some of whom may be related parties, though not explicitly detailed as such in the related party section.
• The September 2025 Equity Purchase Agreement with Ascent Partners Fund LLC is not explicitly identified as a related party transaction in the filing's 'Certain Relationships and Related Person Transactions' section, but Ascent is the 'Selling Stockholder' in this S-1 filing.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk (up to 542%) from the ELOC and other recent capital raises. Also exposed to the risk of Nasdaq delisting, which could severely impact share price and liquidity. The going concern warning indicates a high risk of investment loss.
• **Employees**: Stock-based compensation is a significant component of executive pay, but the company's financial instability and cost reduction plans (e.g., workforce reduction in 2023) suggest potential job insecurity. Stock option repricing may affect employee morale and retention.
• **Customers**: Reliance on a single manufacturing partner (Laurus Bio) could pose supply chain risks, potentially affecting product availability and consistency. However, efforts to diversify suppliers aim to mitigate this.
• **Creditors**: The company's going concern doubt and existing debt obligations (e.g., Amended Senior Note with Ginkgo) indicate elevated credit risk. Interest payment deferrals highlight liquidity constraints.
• **Suppliers**: The Seneca Transaction involved purchasing outstanding payables from vendors, indicating past payment challenges, but also a mechanism to resolve them.

Next Steps

• Await decision from the Nasdaq Hearings Panel regarding the delisting appeal.
• Continue efforts to raise additional capital through equity offerings, debt financing, or other means to address going concern doubts.
• Execute on the Equity Line of Credit with Ascent Partners Fund LLC to secure up to $20.0 million in proceeds.
• Continue to develop and expand the Vegan Silk Technology Platform, including efforts to reduce cost of goods and introduce new products.
• Diversify and strengthen the manufacturing network by validating a second supplier and evaluating a third, to reduce reliance on a single partner.
• Remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company faces an existential threat with a 'substantial doubt about our ability to continue as a going concern' and an active Nasdaq delisting process. While recent operational improvements show some promise, the company's cash position is critically low, necessitating highly dilutive capital raises (up to 542% potential dilution from the ELOC alone). The combination of severe liquidity issues, regulatory non-compliance leading to delisting risk, and the certainty of massive shareholder dilution makes this a 'strong sell' for any investor, as the risk of significant capital loss is extremely high.

Keywords

Biomaterials, Vegan Silk, Biotechnology, Beauty and Personal Care, Silicone Replacement, SEC Filing, Nasdaq Delisting, Equity Line of Credit, Going Concern, Financial Reporting, Intellectual Property, Manufacturing, Corporate Governance, Risk Management, BSLK